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ABSTRACT
E2F transcription factors are known to be
important for timely activation of G1/S and G2/M
genes required for cell cycle progression, but
transcriptional mechanisms for deactivation of cell
cycle-regulated genes are unknown. Here, we show
that E2F7 is highly expressed during mid to late
S-phase, occupies promoters of G1/S-regulated
genes and represses their transcription. ChIP-seq
analysis revealed that E2F7 binds preferentially
to genomic sites containing the TTCCCGCC motif,
which closely resembles the E2F consensus site.
We identified 89 target genes that carry E2F7
binding sites close to the transcriptional start site
and that are directly repressed by short-term
induction of E2F7. Most of these target genes are
known to be activated by E2Fs and are involved
in DNA replication, metabolism and DNA repair.
Importantly, induction of E2F7 during G0-G1/S
resulted in S-phase arrest and DNA damage,
whereas expression of E2F7 during G2/M failed to
disturb cell cycle progression. These findings
provide strong evidence that E2F7 directly controls
the downswing of oscillating G1/S genes during
S-phase progression.
INTRODUCTION
Since the discovery of E2F nearly 25 years ago as a
biochemical activity able to bind the Adenovirus E2
promoter and control the expression of genes involved
in S-phase, a considerable amount of information has
accumulated in support of a pivotal role for this protein
family in the temporal control of gene expression during
the cell cycle (1). Since that time, eight E2F family
members have been identiﬁed in mammals (2). The clas-
sical E2Fs (E2F1-6) regulate transcription of their target
genes when bound to their promoters as dimers with a
DP protein, whereas atypical E2Fs (E2F7-8) bind to
promoters as homodimers or heterodimers without DP
(3–5). At the structural level, the similitude of the
atypical E2Fs with the classical E2Fs is limited to its
DNA-binding domains (DBD), and here the atypical
E2Fs are further distinguished from its relatives by
possessing two DBD rather than one (6–11).
Many studies have detailed the role for E2F activities in
controlling gene expression at G1/S, involving the activa-
tion of genes encoding DNA replication proteins, enzymes
responsible for DNA biosynthesis, proteins that assemble
to form functional origin complexes and kinases that are
involved in activation of DNA replication. In addition to
this role for E2F, a substantial number of E2F-induced
genes are normally regulated at G2 of the cell cycle,
encoding proteins known to function in mitosis (12–15).
Consistent with these observations, global gene expression
proﬁling and genome-wide promoter occupancy studies
[chromatin immunopreciptation (ChIP)-on ChIP and
ChIP-sequencing] have conﬁrmed that many genes that
are crucial for proper cell cycle progression are bona ﬁde
targets of E2F1, E2F4 and E2F6 (13,16–19). Despite
the considerable progress that has been made toward
understanding how classical E2Fs regulate the cell cycle,
the identity of genes regulated by atypical E2Fs is still
unknown.
To obtain a complete understanding of the role of
the atypical E2Fs in cell cycle control, it will require the
identiﬁcation of the full range of E2F target genes. One
issue that may complicate attempts to determine the role
of the individual E2Fs is that loss of one family member
may lead to compensation by another, either as a result of
increased levels of one family member for the other or
replacement of one family member for the other at
particular promoters. In fact, previous studies show that
long-term loss of E2F7 leads to compensatory function by
E2F8 and vice versa to ensure cell viability and survival
of the organism (20). Furthermore, we and others
demonstrated the existence of a direct transcriptional
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Therefore, we have taken an unbiased approach of ChIP
in combination with sequencing (ChIP-seq) that allows
the identiﬁcation of in vivo binding sites for E2F7
without altering the ratios of the E2Fs to each other.
E2F8 target genes could not be determined, because all
commercial and home-made antibodies against E2F8
were not of sufﬁcient quality to perform ChIP-seq
assays. To validate the obtained E2F7 targets and to
determine their functional signiﬁcance, we generated
inducible E2F7 cell lines and evaluated the direct effects
of short-term induction of E2F7 on target gene expression
and cell cycle progression.
MATERIALS AND METHODS
Generation of cell lines
Mouse E2F7 cDNA (Reference sequence: NM_178609.4)
was ampliﬁed with primers that introduced a HindIII site
at the 50 and a BamHI site at the 30-end, using Pfu poly-
merase (Fermentas). The cDNA was then cloned into the
pEGFP-N3 plasmid (Invitrogen) using a double digestion
with these two enzymes, followed by ligation with T4
ligase (Fermentas), in such a way that a C-terminal
E2F7-EGFP fusion protein would be transcribed. In
addition to wild-type E2F7, we used a E2F7 cDNA with
both DNA binding domains mutated as described
previously (20), which served as a negative control.
Subsequently, EGFP, E2F7-EGFP and E2F7-DBD
mutant-EGFP were digested out from the pEGFP
plasmid by a double enzymatic digestion with HindIII
and XhoI, and subsequently ligated into the pcDNA4/
TO plasmid (Invitrogen) using T4 ligase. Successful
cloning was conﬁrmed with sequencing (Baseclear,
Leiden, The Netherlands). Tet repressor-expressing
HeLa cells (T-REx HeLa, Invitrogen) were transfected
with these constructs, and stable clones were established
by Zeocin selection (Invitrogen, 300mgml
 1). The cells
were cultured in DMEM containing 10% Tet System
Approved fetal bovine serum (Clontech). Overexpression
was induced by adding 0.2mgml
 1 doxycycline (Sigma) to
the cell culture medium. Cells were synchronized by serum
starvation followed by hydroxyurea block as following:
ﬁrst near-conﬂuent cells were cultured for 36h in
serum-deprived medium (0.5% FBS). Then, cells were
subcultured and allowed to attach to the culture dishes
in DMEM containing 10% FBS for 3h. Subsequently,
2mM hydroxyurea (Sigma Aldrich) was added to the
medium for 16h to arrest cells at the onset of S phase.
Cells were released from the HU block by washing three
times with PBS and adding fresh medium containing 10%
FBS. In an additional experiment, cells were synchronized
in G0 by reducing the concentration of FBS to 0.1% for
72h. Subsequently, the serum concentration was increased
to 10% to allow cell cycle reentry.
E2f7
loxP/loxP E2f8
loxP/loxP mouse embryonic ﬁbroblasts
were isolated and maintained as described previously (20).
Immortalization with retroviral constructs containing
Myc and Ras
61L was performed as described previously
(20,22). The immortalized lines were then treated with
retrovirus containing the Cre recombinase to generate
E2f7/8 double knockout cells, according to standard
methods (23).
Flow cytometry
For measurement of DNA contents, cells were trypsinized,
washed with PBS, ﬁxed with 70% ethanol and stored at
4 C up to 1 week. Cells were washed twice with PBS,
and then reconstituted in PBS containing 20mgml
 1
propidium iodide, 250mgml
 1 RNase A and 0.1%
bovine serum albumin (BSA). Staining and quantiﬁcation
of g-H2AX was done according to the protocol described
by MacPhail et al. (24). Brieﬂy, cells were ﬁxed with
ethanol, permeabilized with 0.1% Triton X-100 and
stained with a rabbit polyclonal antibody directed
against g-H2AX (NB 100-2280, Novus Biologicals).
After washing, cells were incubated for 1h with anti-
rabbit conjugated to Dylight 649 (711-495-152, Jackson
Laboratories). After rewashing, cells were stained with
1mgml
 1 40,6-diamidino-2-phenylindole (DAPI), and
analyzed immediately on a ﬂow cytometer. All samples
were analyzed on a BD FACS Canto II or a FACScan
ﬂow cytometer. Cell cycle analysis was done using
FlowJo 7.6.
Quantitative PCR and microarray
Isolation of RNA, cDNA synthesis and qPCR were
performed as previously described (25). Gene expression
was calculated using a Ct method adapted for
multiple-reference gene correction (26). All samples were
corrected for two reference genes: b-Actin, and 18S ribo-
somal RNA. Primer sequences are provided in
Supplementary Table S7.
Gene expression microarrays were performed using
human 70-mer oligos (Operon, Human V2 AROS)
spotted onto Codelink activated slides (Surmodics
USA). RNA ampliﬁcations, labeling and hybridizations
were performed on an automated system (Caliper Life
Sciences NV/SA, Belgium) with 3mg total RNA from
each sample, as previously described (27). Hybridizations
were done on a HS4800PRO system (Tecan Benelux
B.V.B.A.) using 1000ng labeled cRNA per channel.
Hybridized slides were scanned on an Agilent scanner
(G2565BA) at 100% laser power, 30% PMT. After auto-
mated data extraction using Imagene 8.0 (BioDiscovery),
printtip Loess normalization was performed on mean
spot-intensities (28). Four biological replicates of vehicle-
and doxycycline-treated samples were compared. Half of
the replicates were labeled with Cy5 against control
RNA (Cy3) on dual channel arrays; the second half was
analyzed with opposite dye labeling.
Data were analyzed using ANOVA (MAANOVA,
version 1.41). In a ﬁxed-effect analysis, sample, array
and dye effects were modeled. P-values were determined
by a permutation F2-test, in which residuals were shufﬂed
5000 times globally. Genes with P<0.05 after FDR
correction and cut-off m value (
2log fold change) of
±0.25 were considered signiﬁcantly changed. The up- or
down-regulated transcripts in doxycycline-treated samples
were analyzed using the DAVID and PANTHER gene
3512 Nucleic Acids Research, 2012,Vol.40, No. 8ontology tools (29–31). Data from the microarray study
are available at the Gene Expression Omnibus, accession
number GSE33448.
Chromatin immunoprecipitation and ChIP-sequencing
ChIP was performed according to Millipore’s EZ ChIP
protocol, with the following speciﬁcations: cells were
crosslinked for 10min by 1% freshly made formaldehyde.
Crosslinking was stopped by 5min of 100mM glycine.
Cells were then washed twice with PBS, and scraped in
1ml of ChIP lysis buffer. Lysates were sonicated for 8min
at maximum power on a Covaris S2 (Covaris). For
ChIP-qPCR 1 million cells were used for each reaction;
for ChIP-seq, 25 million cells were used for each reaction.
IPs were performed using BSA-blocked Fast Flow
Agarose G beads (Millipore, 16-266). A rabbit polyclonal
E2F7 antibody (sc-66870, Santa Cruz) was used for
immunoblotting (1:1000), conventional ChIP (1mg per
reaction) and ChIP-seq (10mg per reaction).
To improve signal-to-noise ratios in the ChIP-seq
experiments, a double-IP protocol was used. Antibody–
chromatin complexes were eluted from the beads using
200ml of buffer containing 1% SDS and 100mM
NaHCO3, and dissolved in 10ml of ChIP dilution
buffer. The IP was then repeated with 5mg antibody,
and processed according to the EZ ChIP protocol.
Library construction and sequencing were performed as
described previously (32). Brieﬂy, immunoprecipitated
chromatin was sheared, end-repaired, sequencing
adaptors were ligated and the library was ampliﬁed by
ligation mediated PCR (LMPCR). After LMPCR, the
library was puriﬁed and checked for the proper size
range and for the absence of adaptor dimers on a 2%
agarose gel, barcoded and sequenced on SOLiD/AB
sequencer in multiplexed way to produce 50-bp long
reads. Sequencing reads were mapped against the
reference genome (hg19 assembly, NCBI build 37) using
BWA package (33). Multiple reads mapping to same
location and strand have been collapsed to single read
and only uniquely placed reads were used for peak-calling.
Cisgenome (34) was used for peak-calling from the
ChIP-seq data. Motif analysis was performed using
CisModule function (35), using the following parameters:
motif number K=15, mean motif length Lambda=10,
maximal motif length allowed=18, Initial motif
length=10, initial module size D=3.0, module
length=100, order of background Markov chain=3,
MCM iteration=500. A combination of custom PERL
and R scripts and Cisgenome functions were used for
additional data analysis. Data from the ChIP-seq study
are available at the Gene Expression Omnibus, accession
number GSE32673.
Immunoblotting
Cells were harvested by washing twice with PBS, and
scraped in a lysis buffer containing 50mM Tris-HCl,
1mM EDTA, 150mM NaCl, 0.25% deoxycholic acid,
1% Nonidet-P40, and protease inhibitors (Roche). Cells
were lysed on ice for 20min, and centrifuged for 10min at
12000g. The supernatants were then immunoblotted with
standard SDS-PAGE techniques. The following anti-
bodies were used: E2F7 (Santa Cruz sc-66870), E2F1
(sc-193), GFP (sc-9996), RAD51 (sc-8349), a-Tubulin
(Sigma-Aldrich T5168), g-Tubulin (T6557), mouse IgG
HRP-linked whole Ab (GE Healthcare, NA931), rabbit
IgG HRP-linked whole Ab (NA934). Visualization was
done by ECL (GE Healthcare RPN2106) and exposure
to a ﬁlm (GE Healthcare).
RESULTS
Genome-wide mapping of E2F7 binding sites
To identify novel E2F7 binding sites in promoters of
target genes, we performed ChIP-seq experiments. Given
that E2F7 expression is regulated in a cell cycle-dependent
manner (6,7), we ﬁrst determined when E2F7 protein
levels peak during the cell cycle to provide sufﬁcient
enrichment required for ChIP-seq experiments. To this
end, HeLa cells were synchronized at the beginning of
S-phase by arresting cells in the presence of hydroxyurea
(HU). Upon removal of the drug, these cells then progress
through S-phase, G2, and mitosis, as evaluated by
propidium iodide staining and ﬂow cytometry (Supple-
mentary Figure S1). Immunoblotting showed that E2F7
protein levels peaked at 4–6h after HU removal, when
cells are in mid to late S-phase (Figure 1A). For compari-
son, E2F1 protein levels peaked at 0–4h during early
S-phase and decreased afterward, when E2F7 accumulates
maximally. These ﬁndings are in line with a feedback
mechanism between these two transcription factors,
where E2F1 activates E2F7 expression and E2F7 represses
E2F1 expression (20). Utilizing siRNAs targeting against
either E2F7 or E2F1, we conﬁrmed antibody speciﬁcity
(data not shown). Based on these expression data, cell
lysates were harvested 6h after HU release to perform
ChIP-seq experiments with an antibody speciﬁc for
endogenous human E2F7. A sequencing library was
created, and after mapping and ﬁltering, 5647197
unique reads were used for peak calling. In addition, we
sequenced a parallel sample of input DNA from the same
cells as a control to ensure that enriched sites are not an
artifact of the processing and sequencing. Thus, ChIP
peak scores were normalized corresponding input peak
scores during the peak calling algorithm, resulting in
1107 signiﬁcantly enriched E2F7 peaks. Almost 50% of
the ﬁltered peaks were located within 1kb from annotated
transcription start sites (Supplementary Figure S2).
A distance of maximum 5kb up- or downstream from a
transcription start site was taken as a cut-off for identiﬁ-
cation of putative E2F7 target genes. Gene ontology (GO)
analysis on the 737 genes identiﬁed this way
(Supplementary Table S1) showed highest fold enrich-
ments for pathways related to DNA metabolism, repair
and replication (Supplementary Table S2). In fact, every
enriched category was directly related to the cell cycle,
with the exception of the GO clusters ‘mRNA splicing’
and ‘Pre-mRNA processing’. Among the 737 genes
identiﬁed, many known E2F target genes were present,
such as CDC6, MCM2 and RAD51 (Figure 1B and
Supplementary Table S1).
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Figure 1. Identiﬁcation of E2F7 target genes by ChIP-seq analysis. (A) E2F7 and E2F1 immunoblots on HU-synchronized HeLa cells.
Alpha-Tubulin immunoblots served as loading control. (B) Examples of E2F7 ChIP peaks near transcription start sites of three different genes.
Chromosome coordinates are indicated above the peaks. The bottom tracks show UTRs, coding regions, and introns indicated by thin or thick
boxes, and lines respectively. The direction of transcription is from left to right in all shown genes. (C) ChIP-qPCR conﬁrmation of a panel of target
genes in HU-synchronized HeLa cells. ChIPs were performed using an E2F7 antibody or non-immune IgGs as controls. ChIP qPCR on a
non-speciﬁc region 700bp upstream of E2F binding sites of the E2F1 promoter (E2F1 exon 1) served as negative control for unspeciﬁc binding.
Graphs represent average±SD (n=2)(D) Position weight matrix of highest overrepresented motif within E2F7 peaks compared with random DNA
regions. (E) Distribution of the E2F7 binding motif among ChIP-seq peaks, based on proximity to nearest transcription start site (TSS).
3514 Nucleic Acids Research, 2012,Vol.40, No. 8We conﬁrmed binding of E2F7 to promoters of these
genes speciﬁcally during S-phase using ChIP followed by
quantitative PCR (Figure 1C). Interestingly, we found
that E2F7 occupied the promoters of E2F1, E2F2, E2F3
and E2F8 as well as its own promoter, supporting our
previous studies showing that atypical E2Fs can regulate
the transcription of the classical activator E2Fs
(Supplementary Table S1) (6,20). Recent ChIP-seq
studies showed that E2F4 binds to promoters of all
E2Fs and all pocket proteins (18). Here, we found that
E2F7 also occupied the promoter of p107 (RBL1), but not
the promoters of other pocket proteins or other classical
E2F repressors (E2F4-6).
E2F7 binds to the consensus E2F site
A de novo motif search of E2F7-enriched DNA regions
yielded a motif closely resembling the classic E2F-
binding consensus sequence TTTSSCGC (Figure 1D). In
total, 15 motifs were found, of which 7 were enriched
>2-fold over random DNA regions (Supplementary
Table S3). Without exception, these seven motifs are
known binding sites for other transcription factors, such
as NF-Y and SP1. A motif resembling the classic consen-
sus E2F binding site showed by far the highest enrichment
(6-fold; Figure 1D and Supplementary Table S3).
Single or multiple copies of this E2F7 binding site motif
were present in 70% of the peaks located within 5kb
from a transcriptional start site, but only in 20% of the
more distant peaks (Figure 1E).
E2F7 represses transcription of G1/S genes
To complement the ChIP-seq studies described above,
we overexpressed E2F7 and analyzed the global gene
expression by microarrays. We generated HeLa cell lines
stably expressing doxycycline-inducible E2F7 constructs
tagged with enhanced green ﬂuorescent protein (EGFP).
Cell lines containing only EGFP constructs, or E2F7 with
mutated DNA binding domains (DBDmutant) construct
served as negative controls. In absence of doxycycline,
stably transfected E2F7 cell lines did not show increased
E2F7 mRNA levels compared to EGFP only cell lines,
conﬁrming that the inducible expression system was not
leaky (Figure 2A). A robust increase in E2F7 protein was
seen as soon as 4h after initiation of doxycycline treat-
ment (Figure 2B). To identify direct targets of E2F7,
we induced E2F7 expression for 8h, when E2F7 protein
just reached maximum levels without yet reducing protein
levels of E2F1, a known direct target of E2F7 (Figure 2B)
(20). Thus indirect transcriptional effects through an
E2F1 feedback loop could be ruled out. Given the
strong enrichment of E2F7 on promoters of genes
involved in DNA replication, we performed expression
studies in an HU-synchronized cell population. HeLa
cells were treated for 16h with HU and during the last
8h of the HU-synchronization E2F7 expression was
induced by adding doxycycline. We then performed gene
expression analysis on four biological replicates of doxy-
cycline- versus vehicle-treated cells by microarrays.
Three hundred and thirty-four transcripts were signiﬁ-
cantly decreased, whereas only 80 were increased
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Figure 2. Validation of E2F7 target genes by microarray analysis
after doxycycline-induced E2F7 overexpression. (A) qPCR analysis
for E2F7 gene expression in cell lines stably expressing doxycycline
inducible E2F7-EGFP (E2F7), E2F7-DBDmut-EGFP (DBDmut), or
EGFP alone, cultured either with doxycycline (DOXY) or vehicle for
24h. Data represent average±SEM (n=3), asterisks indicate P<0.05
versus vehicle (B) GFP and E2F1 immunoblots on HeLa cell lysates
harvested at different time points after doxycycline-induced E2F7-
EGFP expression. Immunoblotting for g-tubulin served as loading
control. (C) Venn diagram to show overlap between down- (red) and
upregulated (green) transcripts identiﬁed by gene expression microarray
after 8h E2F7 overexpression and transcripts related to genes with
a E2F7 ChIP peak (blue) within 5kb from their transcription start
site (TSS). (D) Percentages of genes containing a ChIP peak within
5kb from the TSS, categorized according to regulation in gene expres-
sion microarray after E2F7 overexpression, i.e., downregulated
(DOWN), no change (NC), or upregulated (UP). Error bars represent
standard deviation of 1000 randomized datasets with resampled gene
names. Triple asterisk indicates P<0.001 calculated from permutation
test. (E) Heat map of PANTHER gene ontology enrichments in micro-
array and ChIP-seq showing similar enrichments of gene ontology
clusters. Only clusters with Benjamini scores <0.05 were considered
signiﬁcantly enriched.
Nucleic Acids Research,2012, Vol.40, No. 8 3515(Supplementary Table S4). GO analysis of the down-
regulated transcripts showed that the most strongly
enriched pathways were related to the cell cycle, especially
DNA replication, repair, and metabolism (Supplementary
Table S5). Analysis of the upregulated transcripts yielded
no signiﬁcantly enriched pathways.
To determine whether there is an overlap between
E2F7 targets identiﬁed in our ChIP-seq and microarray
experiments, we performed comparative analysis on both
data sets. Remarkably, 89 transcripts (27%) that were
downregulated after E2F7 overexpression also had an
E2F7 peak within 5kb from its transcription start
site, whereas upregulated genes showed no overlap
(Figure 2C and D). These genome-wide studies provide
strong evidence that E2F7 acts strictly as a transcriptional
repressor. The widespread overlap in targets points to the
high degree of speciﬁcity achieved in our ChIP-sequencing
and microarray experiments. On the basis of these
ﬁndings, we propose that these 89 transcripts are the top
E2F7 gene targets (Table 1). Importantly, the expression
of the majority of these E2F7 target genes are known to
be regulated at G1/S phase of the cell cycle (Table 1),
suggesting that E2F7 is critical to down-regulate these
genes during late S-phase, at the time of the cell cycle
when E2F7 accumulates maximally (Figure 1A).
Functional annotation on the overlapping target genes
derived from both genome-wide studies conﬁrmed again
a strong enrichment for gene products known to be
involved in DNA replication, metabolism and repair
(Figure 2E and Supplementary Table S6). Interestingly,
both microarray and ChIP-seq experiments showed
enrichment of target genes involved in mRNA processing
and regulation of splicing (e.g. DHX15, HNRNPD and
several SFRS isoforms), suggesting a regulatory role for
E2F7 in controlling mRNA splicing, as described
previously for E2F1 (36).
We then used quantitative PCR analysis to assess
the effect of acute induction of E2F7 on the transcription
of target genes in a time-dependent manner. We took
advantage of our inducible cell lines containing either
Table 1. Identiﬁcation of top E2F7 target genes by combination of ChIP-seq and gene expression microarray
Gene symbol Peak
mRNA
E2F7
motifs
Gene symbol Peak
mRNA
E2F7
motifs
Gene symbol Peak
mRNA
E2F7
motifs
DNA replication and metabolism Cell cyle regulation Miscellaneous/unknown
CDC6 G1/S
a,b 2 CCNE1 G1/S
a,b,c 0 ARGLU1 1
CDC7 G1/S
a,b 4 CCNE2 G1/S
a,b 11 ATAD2 G1/S
b 1
CDT1 1 CDKN1A 3 C3orf58 3
CHAF1B G1/S
a,b 1 E2F3 7 CDCA7 4
DBF4 1 E2F7 1 CDCA7L 3
DTL G1/S
b 3 E2F8 G1/S
a,b 3 CREBZF 1
DUT 2 WEE1 G2/M
a,b 2 DEK 8
FEN1 G1/S
a,b,c 1 FBXL3 1
GINS2 1 Nucleobase, nucleotide and nucleoside biosynthesis GPD2 2
MCM2 G1/S
a,b 1 DHFR S
a 1 GPR180 3
MCM3 G1/S
b,c 5 GMPS 1 KBTBD2 2
MCM4 G1/S
b,c 3 MTHFD1 G1/S
b 2 KITLG 3
MCM6 G1/S
a,b,c 0 KPNB1 M/G1
a 2
MCM7 G1/S
c 5 Chromatin organization LUC7L2 3
ORC1L G1/S
a,b 2 ASF1B G2/M
b 3 MLF1IP G2/M
b 3
PCNA G1/S
a,b,c 4 CBX3 M/G1
a 1 MTAP 4
POLA1 G1/S
a,c 1 DNMT1 G1/S
c 0 NUP160 2
POLD2 0 HELLS G1/S
b 2 PLCXD1 0
PRIM1 S
a 1 YEATS4 G1/S
b 3 PLSCR1 2
PSMC3IP 2 RHEB 2
RBBP4 1 RNA processing/splicing SCML1 4
RFC2 S
a 3 DHX15 2 SERTAD4 1
RFC4 S
a 2 EXOSC9 G1/S
b 1 SIVA1 3
HNRNPD 3 STARD7 0
DNA repair HNRPDL 1 TCF19 2
BLM G1/S
b 3 INTS7 3 TMEM194A 2
CHEK1 3 SLBP G1/S
a,b,c 2 TMPO G2/M
a,b 1
EXO1 G1/S
a,b 2 TNFAIP8 4
FANCI 2 Cytoskeleton organization UBE2T 0
FANCL 2 FBXO5 G1/S
b 7
MSH2 G1/S
a 3 RANBP1 3
MSH6 G1/S
b,c 3 SAC3D1 2
RPA2 G1/S
a,b 2 SPC25 1
UNG G1/S
a,b 0 TUBA1B 2
USP1 G1/S
a,b 2 TUBB G2/M
a,b 2
Peak mRNA indicates whether mRNA levels of the depicted genes peak during speciﬁc cell cycle stages, according to at least one of three different
publications:
aWhitﬁeld et al. (38);
bBar-Joseph et al. (42); or
cIshida et al. (12). Third column indicates the number of E2F7 binding motifs in
ChIP-seq peaks within 5kb from the TSS of depicted genes. Gene names and complete overview of associated GO terms of each gene can be found
in Supplementary Table S6.
3516 Nucleic Acids Research, 2012,Vol.40, No. 8wild-type E2F7 or E2F7-DBD-mutant. The cell lines were
synchronized by HU block and during the last hours of
HU synchronization E2F7 was induced by adding doxy-
cycline for 4, 8 or 12h. As seen in Figure 3A, the expres-
sion of transcripts involved in DNA replication or DNA
repair started already to decrease after 4h of doxycycline
treatment. Previous studies demonstrated that E2F1,
E2F2 and E2F3 control expression of genes involved
in DNA replication as well as mitosis and cytokinesis
(12–14). We therefore examined the expression of a
panel of genes implicated in mitosis/cytokinesis, but
failed to detect a signiﬁcant decrease in gene expression
after E2F7 induction (Figure 3A). Induction of E2F7
DBD mutant in HeLa cells had no effect on E2F target
gene expression (Figure 3A and Supplementary Figure
S3). These results conﬁrmed our genome-wide studies
showing that transcripts involved in DNA replication,
metabolism and repair are direct targets of E2F7,
whereas mitotic or cytokinetic genes are not regulated
by E2F7.
One possibility for the failure of E2F7 to repress G2/M
genes might be that we performed our studies in
HU-arrested cells. We, therefore, induced expression of
E2F7 during G2/M phase at the time when mitotic/
cytokinetic gene products such as CCNB1, PLK1, and
ECT2 accumulate maximally (37–39). To this end, cells
were ﬁrst synchronized by HU, and then released from
the HU-block for 9h, and E2F7 expression was induced
during the last 9h. About 70% of the cells treated with
doxycycline were in G2/M phase of the cell cycle and
expressed E2F7-EGFP (Figure 3B). Quantitative PCR
analysis revealed that mRNA levels of CCNB1,
PLK1 and ECT2 (Figure 3B), as well as Aurora kinase A
and RACGAP1 (data not shown) were again not
downregulated by E2F7 overexpression. In contrast,
RAD51 and E2F1 mRNA were signiﬁcantly decreased
9h after hydroxyurea release. Consistent with these
ﬁndings, we found that E2F7 overexpression in asyn-
chronously growing cells resulted in downregulation
of G1/S genes but not G2/M genes (Supplementary
Figure S3).
Given the above observations, we examined whether
genetic disruption of E2f7 increases expression of G1/S
genes but not G2/M genes. Previous studies showed
that E2F8 can compensate for the loss of E2f7 (20). We,
therefore, generated E2f7
 /  E2f8
 /  mouse embryonic
ﬁbroblasts and measured gene expression on a panel of
G1/S and G2/M genes by quantitative PCR. Messenger
RNA levels of G1/S genes were  3-fold increased
compared to wild-type cells, whereas mRNA levels of
G2/M genes were not affected or only modestly increased
(Figure 3C).
Subsequently, we studied whether the increased expres-
sion of the G1/S genes was maintained during the later
phases of the cell cycle. To this end, we arrested
wild-type and E2f7
 /  E2f8
 /  mouse embryonic ﬁbro-
blasts at the onset of M-phase with 16h of nocodazole
treatment. Again, expression of Cdc6, Cdt1 and Mcm2
was signiﬁcantly increased in the E2f7
 /  E2f8
 /  cells
(Figure 3D).
From these results, we conclude that E2F7 directly
represses the expression of speciﬁc G1/S genes involved
in DNA replication, metabolism and repair.
E2F7 overexpression leads to S-phase arrest
Given the above observation, we hypothesize that E2F7
overexpression might impair DNA replication. To test this
possibility, we induced E2F7 expression in a synchronized
population of cells stimulated to progress through the cell
cycle. We synchronized cells in G1/S by serum deprivation
followed by restimulation with medium containing 10%
serum and HU. Cells were then washed and incubated
with medium lacking HU and harvested at various times
following HU release. E2F7 expression was induced by
adding doxycycline to the medium 12h before the HU
release. Cell cycle progression was monitored by ﬂow
cytometry (Figure 4A). Strikingly, E2F7 overexpression
arrested cells in early S-phase, indicating that E2F7 has
an important role in regulating DNA replication. As
expected, cells treated with vehicle and cells expressing
the doxycycline inducible E2F7-DBD mutant progressed
normally through the cell cycle and passed through
a complete round of DNA replication within 9h after
HU release.
To investigate whether E2F7 overexpression also affects
G2/M progression, we induced E2F7 expression at a later
time point by adding doxycycline at the onset of
hydroxyurea release (Figure 4B). Despite robust induc-
tion of E2F7 protein during G2/M (Supplementary
Figure S4A), cell cycle progression was not disturbed,
supporting our previous observation that E2F7 function
is not critical for regulating transcription of G2/M genes.
To evaluate whether E2F7 overexpression also affects
entry of quiescent cells into the cell cycle, we induced
E2F7 expression in serum starved cells and found that
cells enter the cell cycle but arrested in S-phase when
cells were stimulated by serum addition (Figure 4C).
Consistent with these observations, E2F7 overexpression
in asynchronized cells dramatically reduced the number of
phospho-histone-3 (PH3) positive cells, underscoring
that E2F7 overexpression induces an S-phase arrest
and thereby prevents entry into G2/M (Supplementary
Figure S4B and C). To ensure that the observed S-phase
accumulation was not a cell type-speciﬁc event of our
inducible HeLa cell lines, we transfected asynchronously
growing 293T kidney epithelial cells with E2F7
(Supplementary Figure S5). In line with our previous
results, we observed a clear S-phase accumulation.
We observed that a small population of E2F7
overexpressing cells continued to pass through the cell
cycle, but E2F7-EGFP ﬂow cytometry analysis revealed
that this population was composed of low expressing
E2F7 cells (Supplementary Figure S6). Together these
studies suggest that E2F7 controls S-phase progression
through repressing E2F target genes involved in DNA
replication and metabolism.
E2F7 overexpression results in DNA damage
Given the overrepresentation of DNA repair genes in the
list of E2F7 target genes generated from our genome-wide
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replication, DNA repair and mitosis at different time point after doxycycline (DOXY) dependent induction E2F7-EGFP (E2F7) or
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Nucleic Acids Research,2012, Vol.40, No. 8 3519studies, we determined whether E2F7 overexpression
would cause DNA damage. We show that induction
E2F7 for 24h resulted in increased DNA double-strand
breaks, analyzed by ﬂow cytometric quantiﬁcation
of ﬂuorescent g-H2AX staining (Figure 5A and B).
Consistent with this observation, immunoblotting
revealed that protein levels of Rad51—a pivotal factor
to repair double strand breaks by homologous
recombination—were markedly decreased upon E2F7
overexpression (Figure 5C). Previous work indicated
that g-H2AX is also activated in apoptotic cells (40).
To examine whether E2F7 overexpression causes cells to
undergo apoptosis, we performed Annexin V staining and
calculated the rate of apoptotic cells by ﬂow cytometry.
E2F7 induction for 24h did not increase the number of
apoptotic cells at the time when increased DNA damage
was detected by g-H2AX staining (Figure 5D). However,
at 48h after E2F7 induction, we observed increased
numbers of apoptotic cells. In line with these ﬁndings, in
cells synchronized by serum starvation and stimulated to
enter the cell cycle by serum addition, we detected a rising
sub-G1 peak between 36 and 48h after E2F7 induction by
PI ﬂow cytometry analysis (Figure 4D). These results
indicate that long term E2F7 overexpression can cause
apoptosis, possibly due to the accumulation of DNA
damage.
DISCUSSION
Here, we have identiﬁed novel genomic binding sites for
the E2F7 transcription factor in promoters of mammalian
cells using ChIP-seq technology. However, the binding of
a transcriptional regulator to the promoter region of
a gene suggests that the factor has regulatory effects on
the gene, but it is also possible that the factor does not
fully or even partially control the gene. For this reason,
we have identiﬁed a set of genes where E2F7 binding
correlates with reduced gene expression after short term
induction of E2F7. The data derived from these two
independent genome-wide approaches were combined
and resulted in a list of 89 genes, which we consider as
the top E2F7 target genes and that encode gene products
involved predominantly in DNA replication, metabolism
and DNA repair. Inducible E2F7 overexpression arrested
cells in S-phase, providing strong evidence for an import-
ant role for E2F7 in controlling S-phase progression
through transcriptional repression of its target genes.
These ﬁndings are supported by our previous studies
showing that ablation of atypical E2Fs in MEFs acceler-
ates S-phase progression (20). Because, E2F7 expression
is regulated in a cell cycle-dependent manner, the
genome-wide studies were performed in synchronized
cell populations, to achieve maximal expression of E2F7
and sufﬁcient enrichment on its targets. A possible
disadvantage of this approach is that we select for E2F7
target genes regulated during S-phase and might miss
E2F7 target genes that are not expressed during this cell
cycle phase.
We have identiﬁed TTCCCGCC as the predominant
E2F7 binding motif. This motif closely resembles the
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3520 Nucleic Acids Research, 2012,Vol.40, No. 8classic E2F binding motif TTTSSCGC, where S is either a
C or a G. Over 70% of all ChIP peaks mapping within
5kb from a transcription start site contained at least
one repeat of this motif. This percentage was even
higher when considering only the 89 genes that were also
down-regulated after E2F7 overexpression (90%). Our
data are in contrast with recent studies utilizing
promoter occupancy assays, which revealed that only a
very small percentage of the regions bound in vivob y
E2F1, E2F4 or E2F6 contained consensus E2F motifs,
suggesting that classical E2Fs are recruited in vivo
predominantly to non-consensus binding sites (16–19).
We retrieved a relatively low number of E2F7-enriched
regions in the ChIP-seq analysis, about 10-fold lower
than reported numbers of peaks in ChIP-seq studies on
E2F1 and E2F4 binding (17,18). Apart from differences in
methodology or antibody characteristics, this could be
explained by different binding properties of atypical
E2Fs compared to E2F-DP heterodimers. In vitro
protein–DNA binding studies suggested different
binding speciﬁcity for combinations of E2F-DP (41). It
is conceivable that E2F7/8 homo- and heterodimers
also have unique DNA binding characteristics.
A substantial number of the E2F7 target genes have
been previously linked to E2F function. A role for
E2F1, E2F2 and E2F3a in activation several of these
DNA replication, metabolism and repair genes has been
well established (23). Strikingly, the transcription of the
majority of these E2F target genes is repressed directly by
E2F7, suggesting that E2F7 counterbalances the tran-
scription of E2F target genes activated by E2F1-3a.
Previous studies have shown that the transcription of
these E2F target genes oscillates during the cell cycle
with peak levels during the G1/S phase transition
(12,38,42). Our studies show that protein levels of E2F7
accumulate maximally at mid to late S-phase coinciding
with the time when the expression of E2F target genes
declines. In line with this, our previous studies
demonstrated that transcription of E2F target genes
such as Cdc6 increased acutely during S and G2 when
atypical E2Fs were deleted in synchronized MEFs (20).
Together, these ﬁndings suggest that classical E2F activa-
tors are essential for the upswing in the oscillating pattern
of the cell cycle-speciﬁc expression of G1/S genes, whereas
the atypical E2Fs contribute directly to the downswing.
Previous work has demonstrated that E2F activators
also control transcription of G2/M-regulated genes
encoding proteins known to function in mitosis (12–15).
We provide substantial evidence that the expression of
G2/M-regulated genes is not controlled directly by E2F7.
First, we show that induction of E2F7 during S-G2/M
does not disturb cell cycle progression, whereas induction
of E2F7 expression during G0 or G1/S arrested cells in
S-phase. Second, E2F7 protein levels dramatically
decrease during G2/M indicating that E2F7 is not
relevant during this phase of the cell cycle. Third,
overexpression of an E2F7 degradation-resistant mutant
that is highly expressed during G2/M failed to block cell
cycle progression during mitosis (B. Westendorp and A.
de Bruin, unpublished data). Finally, our genome-wide
studies revealed that the majority of the G2/M genes are
not repressed by E2F7 and do not contain E2F7 binding
sites in their promoters. These observations are supported
by a previous study showing that E2F1 but not
E2F7 bound to promoters of CDC2 and CCNA2, two
G2/M-regulated genes (7). However, it is possible that
manipulation of E2F7 expression levels has indirect
effects on the regulation of G2/M through altering expres-
sion of G1/S genes. In fact, we observed that long
term overexpression of E2F7 down-regulated expression
of both G1/S and G2/M genes, suggesting that
E2F7-mediated repression of E2F activators leads subse-
quently to decreased expression of G2/M genes. This is in
line with work from Zhu et al. (14) demonstrating that
E2F activators link the control of G1/S and G2/M
transcription.
Our experiments also demonstrate that E2F7 represses
directly important players in the DNA damage response—
most notably RAD51, CHEK1 and the BRCA1 and
-2 genes. In line with this, E2F7 overexpression caused a
marked increase in DNA damage. Consistent with these
observations, Zalmas et al. (21) showed that inactivation
of atypical E2Fs prevents cell cycle effects that occur in
response to DNA damage. Negative feedback regulation
of DNA repair is essential, which is illustrated by studies
that demonstrate that inappropriate expression of the
E2F7 targets such as RAD51 and BLM contribute to
genomic instability (43,44). Furthermore, increased levels
of many DNA repair genes in tumors are often associated
with poor prognosis (45,46).
Our previous microarray analysis on E2f7
 / E2f8
 / 
mouse embryos demonstrated deregulation of predomin-
ately gene products known to be activated in response to
stresses, including hypoxia, nutrient deprivation and
apoptosis (20). In contrast, our current genome-wide
studies in human cells show that E2F7 is critical for
controlling transcription of G1/S genes and we observed
no enrichment for genes involved in cellular stress
responses. This discrepancy is most likely related to fact
that E2f7
 / E2f8
 /  embryos show multifocal severe
E2F1-dependent apoptosis and vascular defects. In
addition, genetic disruption of atypical E2fs in mice
leads to a severe placental phenotype (G. Leone,
personal communication), indicating that oxygen and
nutrient supply is reduced in E2f7
 / E2f8
 /  embryos
resulting in activation of a cellular stress response, as we
have previously described in Rb deﬁcient mice (47,48).
Furthermore, we have deleted atypical E2fs in the liver
utilizing albumin-cre transgenic mice and found that the
majority of the top E2F7 targets were upregulated in
postnatal livers of E2f7
 / E2f8
 /  mice (S. Pandit and
A. de Bruin, unpublished data). These ﬁndings point
towards a direct role of E2F7 to control transcription of
G1/S genes rather than regulating stress related genes.
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